---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-050057"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2024-12-20T23:59:59+00:00"
generated_at: "2026-05-29T00:44:20.308088+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# FDA approves Ionis' Tryngolza (olezarsen) as first treatment for familial chylomicronemia syndrome

## Summary
- Phase 3 Balance trial: placebo-adjusted mean triglyceride reduction 42.5% at 6 months (p=0.0084), 57% at 12 months.
- Acute pancreatitis events: 1 patient (5%) on Tryngolza vs 7 patients (30%) on placebo over 12 months.
- Most common adverse reactions: injection site reactions (19% vs 9%), decreased platelets (12% vs 4%), arthralgia (9% vs 0%).
- U.S. launch expected before year-end; first of four independent launches planned over next three years.
- FCS affects up to ~3,000 people in U.S.; Tryngolza is self-administered monthly via auto-injector.

## SEC filing metadata
- accession: 0001140361-24-050057
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2024-12-20T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036124050057/0001140361-24-050057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036124050057/ef20040455_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-050057
- JSON: https://secwatch.observer/filing/0001140361-24-050057.json
- Plain text: https://secwatch.observer/filing/0001140361-24-050057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.